Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adicet Bio (ACET – Research Report), Palvella Therap...

Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Palvella Therapeutics today and set a price target of $130.00. Slutsky covers the He...

Market Cap	$937.64M	P/E Ratio	N/A
52W High	$106.71	52W Low	$11.17
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-122.6%	52W Position	91.5%
Overall Score	54	Value Score	40
Quality Score	57	Technical Score	66

EPS Current Est	$-3.46	EPS Next Est	$-3.61
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PVLA	$98.58	+1.86%	189.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PVLA	$98.58	+1.9%	189.13K
3
4
5
6

PVLA

PVLA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Palvella Therapeutics Inc. Data in Excel

Get Palvella Therapeutics Inc. Data in Excel